Pay in 4 interest-free payments of $24.75 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
from day 5) reduces tumor size and weight by 53% and 40%
InChiKey: CZQHHVNHHHRRDU-UHFFFAOYSA-N
Epub 2014 Mar 26
Currently CUDC-907 is in phase I clinical trials for patients with solid tumors or lymphoma
TRIM24-C34 - BRPF1B/TRIM24 Dual Inhibitor. CAS# 1242907-48-7 ry of Histone Demethylase from day 5) reduces tumorTRIM24 C34, CAS No. 1242907 48 7, is a potent, selective and cell permeable BRPF1B and TRIM24 dual inhibitor. TRIM24 C34 binds to bromodomain BRPF1B with a Kd of 137 nM, and the transcriptional regulator TRIM24 (also an E3 ubiquitin ligase) with a Kd of 222 nM. It has very good selectivity against other 45 bromodomains. Cellular activity of TRIM24 C34 was demonstrated using FRAP assays as well as cell viability data. It showed no significant